Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESODEC: WT1-targeted DC vaccination for Mesothelioma
NCT02649829Phase 2Completed
- Start
- Oct 2017
- Primary completion
- Mar 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of WT1 mRNA-loaded autologous monocyte-derived dendritic cells in malignant pleural mesothelioma (MPM). Started Oct 2017; status: completed.
02
Drugs
WT1 mRNA-loaded autologous monocyte-derived dendritic cells
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02649829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02649829.